Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Key Points
LAG-3 and PD-L1 expression levels were analyzed based on the site of collection, revealing notable variations.
High prevalence rates of LAG-3 and PD-L1 in patients could indicate tailored immunotherapy strategies.
The analysis utilized biomarker assessments to enhance understanding of melanoma treatment response.
Findings may support further investigations into the relationship between biomarker expression and therapy outcomes.
Abstract
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.